Skip to main content
TipRanks
Go Ultimate75% OFF

SCYNEXIS (0L49) AI Stock Analysis

0 Followers
GB:0L49

SCYNEXIS

(LSE:0L49)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Non-dilutive pipeline fundingThe BARDA cost-share contract can fund SCY-247 development through Phase 2 and potentially regulatory submissions while limiting reliance on shareholder dilution. It also supports progress in invasive candidiasis and reinforces SCYNEXIS’s position in drug-resistant fungal infections.
Negative Factors
Revenue contractionThe steep TTM revenue decline shows that commercial and licensing income remains highly unstable, limiting visibility into the company’s recurring revenue base. Persistent top-line weakness can delay operating leverage, reduce internal funding capacity, and make future performance more dependent on pipeline milestones.

SCYNEXIS (0L49) vs. iShares MSCI United Kingdom ETF (EWC)

-50%-25%0%25%50%75%100%GB:0L49-33.15%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$20.19M
Dividend Yield
―
Average Volume (3M)
4,393
Price to Earnings (P/E)
-2.7
Beta (1Y)
0.80
Revenue Growth
543.96%
EPS Growth
72.49%
Country
UK
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

SCYNEXIS Business Overview & Revenue Model

Company Description

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive can...

SCYNEXIS Risk Analysis

SCYNEXIS disclosed 44 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

SCYNEXIS Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0L49 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AYTUAYTU62Neutral$19.35M-1.30-52.89%―-13.27%27.11%
CPIXCPIX53Neutral$88.10M1.28202.58%23.57%-39.11%-241.27%
RMTIRMTI52Neutral$28.33M-4.75-16.04%―-3.96%7.97%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TXMDTXMD50Neutral$21.64M230.860.45%―33.94%-59.77%
IMCCIMCC39Underperform$936.11K-0.02841.81%―-35.33%-127.87%

* Healthcare Sector Average

Performance Comparison

0%200%400%GB:0L49RMTITXMDAYTUCPIXIMCCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0L49 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0L49SCYNEXIS Inc3.20-1.51-32.00%
RMTIRockwell Medical7.03-1.63-18.78%
TXMDTherapeuticsmd Inc1.870.3523.03%
AYTUAytu BioScience1.78-0.20-10.10%
CPIXCumberland Pharmaceuticals Inc.5.884.41299.19%
IMCCIm Cannabis Corp0.57-29.39-98.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.